Open Access
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 1008 - 1013
Section Les anticorps dans les maladies autres qu’oncologiques
Published online 06 January 2020
  1. Salazar G, Zhang N, Fu T-M, et al., Antibody therapies for the prevention and treatment of viral infections. NPJ Vaccines. 2017;2:19. [CrossRef] [PubMed] [Google Scholar]
  2. Pelegrin M, Naranjo-Gomez M, Piechaczyk M , Antiviral monoclonal antibodies: can they be more than simple neutralizing agents? Trends Microbiol. 2015;23:653–665. [Google Scholar]
  3. Tang PK , Palivizumab prophylaxis in preterm infants. Lancet Respir Med. 2017;5:171. [PubMed] [Google Scholar]
  4. Sloan SE, Hanlon C, Weldon W, et al., Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine. 2007;25:2800–2810. [CrossRef] [PubMed] [Google Scholar]
  5. Carrillo J, Clotet B, Blanco J , Antibodies and antibody derivatives: new partners in HIV eradication strategies. Front Immunol. 2018;9:2429. [CrossRef] [PubMed] [Google Scholar]
  6. Schoofs T, Klein F, Braunschweig M, et al., HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science. 2016;352:997–1001. [Google Scholar]
  7. Caskey M, Schoofs T, Gruell H, et al., Antibody 10–1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017;23:185–191. [CrossRef] [PubMed] [Google Scholar]
  8. Nishimura Y, Martin MA , Of mice, macaques, and men: broadly neutralizing antibody immunotherapy for HIV-1. Cell Host Microbe. 2017;22:207–216. [CrossRef] [PubMed] [Google Scholar]
  9. Yamamoto BJ, Shadiack AM, Carpenter S, et al., Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre- and postexposure prophylaxis in animal models of inhalational anthrax. Antimicrob Agents Chemother. 2016;60:5796–5805. [CrossRef] [PubMed] [Google Scholar]
  10. Migone TS, Subramanian GM, Zhong J, et al., Raxibacumab for the treatment of inhalational anthrax. N Engl J Med. 2009;361:135–144. [Google Scholar]
  11. Lowy I, Molrine DC, Leav BA, et al., Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197–205. [Google Scholar]
  12. Delmas Y, Vendrely B, Clouzeau B, et al., Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant. 2014;29:565–572. [CrossRef] [PubMed] [Google Scholar]
  13. Wagner EK, Maynard JA , Engineering therapeutic antibodies to combat infectious diseases. Curr Opin Chem Eng. 2018;19:131–141. [CrossRef] [PubMed] [Google Scholar]
  14. Kohler PL, Greenwood SD, Nookala S, et al., Staphylococcus aureus isolates encode variant staphylococcal enterotoxin B proteins that are diverse in superantigenicity and lethality. PloS One. 2012;7:e41157. [CrossRef] [PubMed] [Google Scholar]
  15. Ali SO, Yu XQ, Robbie GJ, et al., Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clin Microbiol Infect. 2019;25(629):e1–e6. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.